Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia Northwest Pharmaceuticals
• Treatments: Citalopram; Dexetimide; Lithium Carbonate

Criteria

Inclusion Criteria:

• 18-75 years of age

• Meets criteria for Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified or Borderline Personality Disorder

• Ability to speak, read and understand the English Language and provide written informed consent

Exclusion Criteria:

• Current, unstable and significant medical condition or illness

• History of Thyroid disorder, seizure disorder, tumors or other CNS condition that predisposes the patient to risk of seizure

• Pregnant or lactating females

• Abnormal clinical laboratory test results

• Intolerance or hypersensitivity to SSRIs or lithium

• History or current diagnosis of bipolar mood disorder, psychosis, schizophrenia or dementia

• Certain mediations my not be used prior or during the study